Literature DB >> 17132474

The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial.

Peter K Sand1, Roger P Goldberg, Roger R Dmochowski, Marilyn McIlwain, Naomi V Dahl.   

Abstract

OBJECTIVE: The objective of the study was to determine the impact of overactive bladder on sexual function from a preliminary analysis of the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin study. STUDY
DESIGN: The Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin study was an open-label, prospective trial of 2878 subjects with overactive bladder, treated with transdermal oxybutynin for 6 months or less. The impact of overactive bladder on sexual function before and after treatment was assessed via item responses from the King's Health Questionnaire and Beck Depression Inventory-II (kappa-test).
RESULTS: At baseline, 586 (23.1%) reported that overactive bladder had an impact on their sex life. Coital incontinence in 569 (22.8%) decreased after treatment to 438 (19.3%). Effects of overactive bladder on subjects' sex lives improved in 19.1% (worsened in 11.2%), and the effect on relationships with partners improved in 19.6% (worsened in 11.9%). Reduced interest in sex, reported by 52.1% at baseline, improved significantly. (all P < .0001).
CONCLUSION: Overactive bladder negatively affects sexual function. Treatment with transdermal oxybutynin improved sexual function and marital relationships.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17132474     DOI: 10.1016/j.ajog.2006.08.013

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  19 in total

1.  Antimuscarinic use and discontinuation in an older adult population.

Authors:  Scott Martin Vouri; Mario Schootman; Seth A Strope; Hong Xian; Margaret A Olsen
Journal:  Arch Gerontol Geriatr       Date:  2018-09-22       Impact factor: 3.250

2.  Differential Prescribing of Antimuscarinic Agents in Older Adults with Cognitive Impairment.

Authors:  Scott Martin Vouri; Mario Schootman; Seth A Strope; Stanley J Birge; Margaret A Olsen
Journal:  Drugs Aging       Date:  2018-04       Impact factor: 3.923

3.  Sexual Desire among Veterans Receiving Prolonged Exposure Therapy for PTSD: Does Successful PTSD Treatment Also Yield Improvements in Sexual Desire?

Authors:  Christal L Badour; Keith S Cox; Jessica R M Goodnight; Jessica Flores; Peter W Tuerk; Sheila A M Rauch
Journal:  Psychiatry       Date:  2019-10-02       Impact factor: 2.458

4.  The effect of overactive bladder treatment with anticholinergics on female sexual function in women: a prospective observational study.

Authors:  Suleyman Sami Cakir; Recep Burak Degirmentepe; Hasan Anil Atalay; Halil Lutfi Canat; Sait Ozbir; Mehmet Gokhan Culha; Emre Can Polat; Alper Otunctemur
Journal:  Int Urol Nephrol       Date:  2018-11-17       Impact factor: 2.370

5.  Establishing the content validity of the King's Health Questionnaire in men and women with overactive bladder in the US.

Authors:  Mary Kay Margolis; Vasudha Vats; Karin S Coyne; Con Kelleher
Journal:  Patient       Date:  2011       Impact factor: 3.883

Review 6.  Review of current status of female sexual dysfunction evaluation in urogynecology.

Authors:  Ranee Thakar
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2009-05

Review 7.  Urinary disorders and female sexual function.

Authors:  Jaclyn Chen; Genevieve Sweet; Alan Shindel
Journal:  Curr Urol Rep       Date:  2013-08       Impact factor: 3.092

Review 8.  Transdermal oxybutynin.

Authors:  Claudine M Baldwin; Gillian M Keating
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  The evolution of transdermal therapy for overactive bladder.

Authors:  Peter K Sand
Journal:  Curr Urol Rep       Date:  2009-09       Impact factor: 3.092

10.  Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin.

Authors:  Tondalaya Gamble; Peter Sand
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.